2017
DOI: 10.1016/j.neuropharm.2015.08.003
|View full text |Cite
|
Sign up to set email alerts
|

Shifting towards a model of mGluR5 dysregulation in schizophrenia: Consequences for future schizophrenia treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
44
0

Year Published

2017
2017
2022
2022

Publication Types

Select...
7
1
1

Relationship

2
7

Authors

Journals

citations
Cited by 38 publications
(48 citation statements)
references
References 210 publications
4
44
0
Order By: Relevance
“…So far, positive allosteric modulators of mGluR5 have shown promise in preclinical studies using animal models of schizophrenia (Lindsley and Stauffer, 2013;Matosin et al, 2017). Although positive allosteric modulators of mGluR5 have not yet reached FDA approval, it is anticipated that mGluR5-based therapeutics might provide a viable alternative option for the treatment of schizophrenia, alone or in combination Kinney et al, 2005;Stefani and Moghaddam, 2010;Rook et al, 2015;Maksymetz et al, 2017).…”
Section: Discussionmentioning
confidence: 99%
“…So far, positive allosteric modulators of mGluR5 have shown promise in preclinical studies using animal models of schizophrenia (Lindsley and Stauffer, 2013;Matosin et al, 2017). Although positive allosteric modulators of mGluR5 have not yet reached FDA approval, it is anticipated that mGluR5-based therapeutics might provide a viable alternative option for the treatment of schizophrenia, alone or in combination Kinney et al, 2005;Stefani and Moghaddam, 2010;Rook et al, 2015;Maksymetz et al, 2017).…”
Section: Discussionmentioning
confidence: 99%
“…In humans, the allele frequency distribution of an intragenic microsatellite of the mGluR5 gene, GRM5, has been associated with schizophrenia (Devon et al, 2001). Several recent genome-wide association studies confirmed the involvement putative SNPs in GRM5 (Matosin et al, 2015b). In animal models, administration of cannabinoids during adolescence were shown to a reduction in hippocampal mGluR5, which was associated with learning deficits (Gleason et al, 2012).…”
Section: Introductionmentioning
confidence: 99%
“…New Positron emission tomography (PET) radiotracers allow the investigation of another type of receptor closely associated with NMDA‐R—the metabotropic glutamatergic receptors type 5 (mGluR5). The mGluR5 receptors are G‐protein coupled receptors abundantly expressed on cortical, hippocampal and striatal regions in the human brain and are highly implicated in the pathophysiology of schizophrenia (Matosin, Fernandez‐Enright, Lum, & Newell, ). The mGluR5 receptors share a structural and functional link with the NMDA‐R (Newell & Matosin, ) and jointly modulate glutamatergic signaling (Newell, ).…”
Section: Introductionmentioning
confidence: 99%